ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán, Paloma Martin-Martorell, Ernest Nadal, Pere Gascón, Jordi Rodon, Jose M Lizcano, Pau Muñoz-Guardiola, Gemma Fierro-Durán, Oriol Pedrós-Gámez, Héctor Pérez-Montoyo, Marc Yeste-Velasco, Marc Cortal, Antonio Pérez-Campos, Jose Alfon, Carles Domenech, Alejandro Pérez-Fidalgo, Ana Oaknin

Open source

DOI: 10.1186/s12885-024-12501-5
Published: 2024-07-22
Container: BMC Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-024-12501-5,
  title = {ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer},
  author = {Alexandra Leary and Purificación Estévez-García and Renaud Sabatier and Isabelle Ray-Coquard and Margarita Romeo and Pilar Barretina-Ginesta and Marta Gil-Martin and Elena Garralda and Joaquim Bosch-Barrera and Teresa Morán and Paloma Martin-Martorell and Ernest Nadal and Pere Gascón and Jordi Rodon and Jose M Lizcano and Pau Muñoz-Guardiola and Gemma Fierro-Durán and Oriol Pedrós-Gámez and Héctor Pérez-Montoyo and Marc Yeste-Velasco and Marc Cortal and Antonio Pérez-Campos and Jose Alfon and Carles Domenech and Alejandro Pérez-Fidalgo and Ana Oaknin},
  year = {2024},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-024-12501-5},
  url = {https://doi.org/10.1186/s12885-024-12501-5}
}

RIS

TY  - JOUR
TI  - ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
AU  - Alexandra Leary
AU  - Purificación Estévez-García
AU  - Renaud Sabatier
AU  - Isabelle Ray-Coquard
AU  - Margarita Romeo
AU  - Pilar Barretina-Ginesta
AU  - Marta Gil-Martin
AU  - Elena Garralda
AU  - Joaquim Bosch-Barrera
AU  - Teresa Morán
AU  - Paloma Martin-Martorell
AU  - Ernest Nadal
AU  - Pere Gascón
AU  - Jordi Rodon
AU  - Jose M Lizcano
AU  - Pau Muñoz-Guardiola
AU  - Gemma Fierro-Durán
AU  - Oriol Pedrós-Gámez
AU  - Héctor Pérez-Montoyo
AU  - Marc Yeste-Velasco
AU  - Marc Cortal
AU  - Antonio Pérez-Campos
AU  - Jose Alfon
AU  - Carles Domenech
AU  - Alejandro Pérez-Fidalgo
AU  - Ana Oaknin
PY  - 2024
JO  - BMC Cancer
DO  - 10.1186/s12885-024-12501-5
UR  - https://doi.org/10.1186/s12885-024-12501-5
ER  -

APA

Leary, A., Estévez-García, P., Sabatier, R., Ray-Coquard, I., Romeo, M., Barretina-Ginesta, P., Gil-Martin, M., Garralda, E., Bosch-Barrera, J., Morán, T., Martin-Martorell, P., Nadal, E., Gascón, P., Rodon, J., Lizcano, J. M., Muñoz-Guardiola, P., Fierro-Durán, G., Pedrós-Gámez, O., Pérez-Montoyo, H., Yeste-Velasco, M., Cortal, M., Pérez-Campos, A., Alfon, J., Domenech, C., Pérez-Fidalgo, A., & Oaknin, A. (2024). ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer. BMC Cancer. https://doi.org/10.1186/s12885-024-12501-5

Source records

crossref · retrieved 2026-09-27T09:11:03.488Z